Literature DB >> 14722441

Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients.

Jean-Michel Fondere1, Marie-France Huguet, Anna Macura-Biegun, Vincent Baillat, Viviane Ohayon, Jacques Reynes, Jean-Pierre Vendrell.   

Abstract

Memory B cells are long-living cells that circulate throughout the body and differentiate into plasma cells after stimulation by antigens, cytokines, and direct cell-to-cell interaction in lymphoid tissues. For HIV-1-infected patients, we assessed whether in vitro polyclonal B cell activation that induces immunoglobulin secreting cells (SCs) also generates HIV-1-specific resting B cells to synthesize antibodies specific to HIV-1. To this end, highly purified B cells from 10 HIV-1-untreated patients were cultured with or without mouse fibroblastic cells expressing the CD40 ligand in the presence of IL-2 and IL-10. The percentage of immunoglobulin SCs we obtained by using the B cell-CD40L stimulation system was equal to 55% to 98% of the circulating memory B cells. Moreover, the anti-HIV-1 IgG, IgA, or IgM antibody SCs represented 1 x 10-2 to 1 x 10-3 of the total immunoglobulin SCs. The anti-HIV-1-specific antibodies detected in cell culture supernatants were directed to gag-, pol-, and env-encoded viral proteins. We found that in AIDS patients, HIV-1-specific resting memory B cells circulate in the blood and can be quantified by their anti-HIV-1 antibody secretion after strong B cell polyclonal stimulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722441     DOI: 10.1097/00126334-200402010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

3.  Early detection of human immunodeficiency virus type 1-specific B-lymphocyte-derived antibodies in a high-risk population.

Authors:  Odd Odinsen; David Parker; Frans Radebe; Mikey Guness; David A Lewis
Journal:  Clin Vaccine Immunol       Date:  2009-05-27

4.  Simultaneous Detection of Antigen-Specific IgG- and IgM-Secreting Cells with a B Cell Fluorospot Assay.

Authors:  Mattia Bonsignori; M Anthony Moody
Journal:  Cells       Date:  2012-03-21       Impact factor: 6.600

5.  HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Authors:  Angeline Rouers; Jéromine Klingler; Bin Su; Assia Samri; Géraldine Laumond; Sophie Even; Véronique Avettand-Fenoel; Clemence Richetta; Nicodème Paul; Faroudy Boufassa; Laurent Hocqueloux; Hugo Mouquet; Christine Rouzioux; Olivier Lambotte; Brigitte Autran; Stéphanie Graff-Dubois; Christiane Moog; Arnaud Moris
Journal:  EBioMedicine       Date:  2017-05-31       Impact factor: 8.143

6.  The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection.

Authors:  Sophia Steyaert; Lieven Verhoye; Els Beirnaert; Helen Donners; Katrien Fransen; Leo Heyndrickx; Guido Vanham; Geert Leroux-Roels; Peter Vanlandschoot
Journal:  J Immunol Methods       Date:  2007-01-09       Impact factor: 2.303

7.  CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection.

Authors:  Alberto Cagigi; Likun Du; Linh Vu Phuong Dang; Sven Grutzmeier; Ann Atlas; Francesca Chiodi; Qiang Pan-Hammarström; Anna Nilsson
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.